₹2,185.00
+₹9.50 (+0.44%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹1,00,189 Cr
P/E
18.05
ROE
23.76%
ROCE
24.88%
About Lupin Ltd
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.
Founded
1983
CEO
M D Gupta
Employees
22,524
HQ
Mumbai, Maharashtra
About Lupin Ltd
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.
Founded:1983
CEO:M D Gupta
Employees:22,524
HQ:Mumbai, Maharashtra
Finished Products
1Sale of Goods
₹70,644.02Cr2Research Services
₹1,476.96Cr3Export Benefits & Incentives
₹714.15Cr4Excise Duty
₹455.51Cr5Miscellaneous Income
₹137.89Cr6Business Compensation&Settlem.
₹106.95Cr7Scrap sales
₹77.15Cr1–7 of 8
Raw Materials
1Raw Material Consumed
₹14,760.32Cr2Purchase of Traded Goods
₹5,965.77Cr3Packing Material Consumed
₹2,010.16Cr4Purchases of Stock in Trade
₹1,525.70CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹2,530
52W Low
₹1,875
Volume1.23M
Avg VolumeN/A
Beta0.54
Dividend Yield0.82%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
18.05x
Valuation
P/B Ratio
4.46x
Valuation
EPS
₹121.40
Valuation
Dividend Yield
0.82%
Valuation
ROE
23.76%
Profitability
ROCE
24.88%
Profitability
Revenue by Segment
Contribution & growth by business line
Pharmaceuticals
+23.0%99.5%
₹27,810.64 Cr
Others
+39.8%0.5%
₹147.39 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
31.1%
International
68.9%
USA40.9%
India31.1%
Others28.0%
Strategic Relations
Collaborations, joint ventures & subsidiaries
P
Proter SPA
Italy
0.00% stakeF
Fermic
Mexico
0.00% stakeG
Gruppo Lepctit (GL S P A)
Italy
0.00% stakeForensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.29x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
11.8%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.